Skip to main content

Table 1 Summary of four cases

From: Significant risk factors for malignant transformation of ovarian endometrioma during dienogest treatment: a case report and retrospective study

  Case 1 Case 2 Case 3 Case 4
Patient’s parity Nullipara Nullipara Nullipara Nullipara
Age at start of DNGT 43 years 44 years 42 years 44 years
Age at MT 44 years 46 years 42 years 46 years
Cyst size before DNGT 7 cm (left), 3 cm (right) 8 cm (left) 4 cm (left) 3 cm (left)
Cyst size at MT 7 cm (left), 3 cm (right) 5 cm (left) 7 cm (left), 2 cm (right) 3 cm (left), 2 cm (right)
Duration of DNGT 14 months 31 months 9 months 33 months
Operation for ovarian carcinoma TAH, BSO, OM, PLA, PALA LSO TAH, BSO, OM, PLA, PALA TAH, BSO, OM
Pathology Clear cell carcinoma Clear cell carcinoma Clear cell carcinoma Clear cell carcinoma
Origin of carcinoma Left ovary Left ovary Left ovary Right ovary
FIGO stage 1C1 1C3 1C1 1C1
Surgical history (age) Bilateral LC (43 years) Left-side LC (40 years) No No
Chemotherapy TC for 6 cycles TC for 3 cycles TC for 6 cycles TC for 6 cycles
Serum CA 125 at MT 515 U/ml 78.5 U/ml 42.4 U/ml 46.3 U/ml
  1. Abbreviations: BSO Bilateral salpingo-oophorectomy, CA 125 Cancer antigen 125, DNGT Dienogest therapy, FIGO International Federation of Gynecology and Obstetrics, LC Laparoscopic cystectomy, LSO Left salpingo-oophorectomy, MT Malignant transformation, OM Omentectomy, PALA Para-aortic lymphadenectomy, PLA Pelvic lymphadenectomy, RSO Right salpingo-oophorectomy, TAH Total abdominal hysterectomy, TC Paclitaxel and carboplatin